DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Intuitive Machines, U.S. Steel, Victoria's Secret and more
▼ + stars: | 2024-09-18 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Intuitive Machines — Shares soared 51% after the space exploration company secured a roughly $5 billion space network contract from NASA. The move is likely intended to push a decision on the politically controversial takeover past the presidential election in November. Victoria's Secret — The intimate apparel maker gained 5% after Barclays upgraded shares to equal weight from underweight, citing a more balanced risk/reward backdrop. The investment firm said VF Corp should start to see benefits from last year's CEO change this fall. Casella Waste Systems — The recycling company fell 5% after announcing a $400 million public offering of its Class A common stock.

Persons: Steward, McGrath RentCorp —, McGrath, Eli Lilly's GLP, — CNBC's Sean Conlon, Michelle Fox, Lisa Han, Yun Li, Jesse Pound, Pia Singh Organizations: NASA, United States Steel, Nippon Steel, Barclays, Medical Properties, Medical Properties Trust, WillScot Holdings, Wolfe Research, Casella Waste Systems Locations: U.S

WASHINGTON — Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. During Tuesday's roundtable, Sanders said his recent conversations with generic drugmakers revealed that Novo Nordisk's pricing is "nothing less than excess corporate greed." “They have studied the math, and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 a month," Sanders said. Sanders’ office declined to say which generic drug companies told him that they could sell Ozempic at a fraction of what Novo Nordisk charges. Novo Nordisk did not immediately respond to a request for comment.

Persons: WASHINGTON — Sen, Bernie Sanders, Sanders, Lars Fruergaard Jorgensen's, Jorgensen, Wegovy, Dale Folwell, Eli Lilly's Organizations: drugmaker Novo Nordisk, Capitol, Novo Nordisk, Health, Education, Labor, Pensions, Wegovy, Nordisk, Yale Locations: U.S, Novo, Denmark, Germany, United Kingdom, North Carolina

☆ UBS says get defensive as global growth disappoints. Gives stocks to buy
▼ + stars: | 2024-09-17 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

As global growth continues to slow, investors should get overweight on defensive names, according to UBS. August marked yet another month of declining global growth, as the Global Manufacturing Purchasing Managers' Index (PMI) reported 49.5 for the month , down from 49.7 in July, according to S & P Global Market Intelligence. Wall Street has taken a bullish stance, as 12 of the 18 analysts covering the stock have issued strong buy or buy ratings, according to LSEG. Constellation Energy has also been on a monster run this year, with shares surging 70%. About 82% of the analysts covering the stock rate it a buy or strong buy, according to LSEG.

Persons: Dow Jones, Eli Lilly, it's Organizations: UBS, Global Manufacturing, P Global Market Intelligence, Institute for Supply Management, Federal Reserve, Constellation Energy, Constellation Locations: Ireland

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ We ranked the latest earnings reports from 30 portfolio stocks from great to ugly
▼ + stars: | 2024-09-14 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

The company may have maintained its full-year revenue outlook, but that was taken as good enough after last quarter's debacle. Management also provided a better-than-expected sales, earnings, and recurring revenue outlook. The Good Abbott Laboratories : Sales, earnings and organic growth all exceeded analyst estimates. Broadcom : Sales and earnings outpaced expectations , driven by strong sales of its AI products and VMware software. Alphabet : Delivered largely better-than expected earnings results that showed the search and cloud giant is finally on better footing in the fast-growing AI space.

Persons: we've, Lisa Su, —, Eli Lilly, Zepbound, Stanley Black, Stanley, Morgan Stanley, Procter, Jim Cramer's, Jim Cramer, Jim, Steve Marcus Organizations: Costco, DuPont, Club, Management, Nvidia, Palo Alto Networks, Good Abbott Laboratories, Broadcom, VMware, Wealth Management, Investment Management, Microsoft, Constellation Brands, TJX, Amazon Web Services, Coterra Energy, GE Healthcare, Honeywell, Gamble, Jim Cramer's Charitable, CNBC, AMD Locations: China, Covid, Dover, Eaton, Palo, North America, GEHC, Wells Fargo, Las Vegas , Nevada, U.S

☆ Here are Friday's biggest analyst calls: Nvidia, Netflix, Tesla, Kroger, Arm, Oracle, Eli Lilly, PNC, GE Vernova & more
▼ + stars: | 2024-09-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Friday's biggest calls on Wall Street: Raymond James initiates Arm as outperform Raymond James said the semis company is well positioned for AI. Citi downgrades Capri Holdings to neutral from buy Citi said the risk/reward is more balanced for the owner of brands like Michael Kors. UBS reiterates Oracle as buy UBS raised its price target on the stock to $200 per share from $175. The feedback on Oracle's top-line growth was overall positive..." UBS reiterates PNC as buy UBS said the bank is a high conviction idea. " Citi resumes Eli Lilly as buy Citi resumed coverage of the stock and says it's well positioned.

Persons: Raymond James, Jefferies, SLG, CFRA, it's, datopotamab, Michael Kors, haven't, Morgan Stanley, EQT, Citi, Eli Lilly, Lilly, Tesla, BEV, Wells Organizations: Arm Holdings, ARM, Citi, Green, Kroger, Macquarie, Rio Tinto, Deutsche Bank, AstraZeneca, Deutsche, Capri Holdings, Barclays, Garmin, GM, BMO, GE, UBS, Oracle, Oracle's, PNC, JPMorgan, Netflix, JPMorgan downgrades Moderna, Nvidia, NVIDIA Locations: GenAI, New York, Rio, RIO, Las Vegas

☆ Morgan Stanley analysts give their favorite stocks to own for the next 12 months
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

From e-commerce firm Amazon to pharmaceutical giant Eli Lilly , Morgan Stanley's top stocks to own for the next 12 months spans a wide array of sectors. The majority of Morgan Stanley's picks are tilted toward growth, with 67% of the picks meeting that classification. Here's a look at some of the stocks that Morgan Stanley says are worth owning over the next year. Amazon stock has added 23% in 2024. LLY YTD mountain Eli Lilly stock.

Persons: Eli Lilly, Morgan, Morgan Stanley's, Morgan Stanley, Brian Nowak's, Nowak, Terence Flynn's, Eli Lilly's, LLY, Flynn Organizations: Nasdaq, Dow Jones, Amazon, Pharma

☆ Cramer: I wouldn't boot any of our 12 core stocks. If anything, I'd add one more
▼ + stars: | 2024-09-13 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +4 min

The 12 core Investing Club portfolio stocks that we identified at our Annual Meeting in February are the 12 we still stand by. Wells Fargo Why we own it We bought Wells Fargo as a turnaround story under CEO Charlie Scharf. Why we own it GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. Fed interest rate cuts can also help hospitals finance the MRI and CT scan machines that GE Healthcare is known for. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Eli Lilly, Jim, Wells, Charlie Scharf, He's, Scharf, Wells Fargo, Lilly, Jim Cramer's Organizations: Apple, Costco, GE Healthcare, Linde, Microsoft, Nvidia, TJX Companies, Bank of America, Citigroup, GE, General Electric, Philips, Siemens, Jim Cramer's Charitable, CNBC Locations: Danaher, Eaton, Wells Fargo

☆ Tech roars back, and Eli Lilly sends a welcome signal on its growth prospects
▼ + stars: | 2024-09-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Jim Cramer said earlier Friday that Nvidia received a do-over from Wall Street . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Nvidia, Financials, Love, Lilly, Eli Lilly, Lilly's, haven't, that's, Jim Cramer's, Jim Organizations: CNBC, Tech, Nvidia, Broadcom, Wall, Federal, Energy, Citi, and Drug Administration, Fed, Market, Jim Cramer's Charitable Locations: Ireland, Kisunla, U.S, Europe

☆ Calls of the Day: Vistra, Garmin, Tesla and Eli Lilly
▼ + stars: | 2024-09-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Vistra, Garmin, Tesla and Eli LillyThe Investment Committee discuss the latest Calls Of The Day.

Persons: Eli Lilly Organizations: Garmin, Tesla

Here's a rapid-fire update on all 32 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. AMD shares have caught a bid in recent days, but they're still cheap considering the growth of its AI processors. Broadcom : Investors who don't own any Broadcom yet should consider starting a position here, Jim said. Although it's tempting to offload shares, Jim said to stick with Honeywell for now because there's huge value in individual businesses like aerospace. There's little negative to say about this portfolio stock.

Persons: Jim Cramer's, Jim, Apple, haven't, it's, that's, he'll, Bob Iger, Bob Chapek, Larry Ellison, Biogen, Eli Lilly, Lowe's, Vimal Kapur, We'd, Linde, Lilly, Morgan Stanley, Goldman Sachs, It's, Jensen Huang, Kamala Harris, Republican Donald Trump, CrowdStrike, Palo, — we're, we're, Brian Niccol, Sands, Stanley Black, Decker, Wells, Charlie Scharf's, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Abbott Laboratories, Abbott Labs, AMD, Amazon, Web, Broadcom, VMWare, Federal Reserve, Costco Wholesale, Coterra, DuPont, New York Times, Oracle, GE Healthcare, GE, Honeywell, Linde, Microsoft, Nvidia, Republican, Palo Alto Networks, Palo, Procter & Gamble, Procter, Gamble, Constellation Brands, Modelo, Stanley, TJX, Marshalls, Jim Cramer's Charitable, Traders, New York Stock Exchange, AFP, Getty Locations: Nvidia's, San Francisco, China, Dover, United States, industrials, OpenAI, Palo Alto, Wells Fargo

☆ Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. Eli Lilly has invested more than $20 billion to buy, build and expand manufacturing plants in the U.S. and Europe since 2020. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , has similarly poured in billions to boost production of its own treatments.

Persons: Eli Lilly, Eli, Edgardo Hernandez, Eli Lilly's Organizations: Novo Nordisk Locations: Indianapolis , Indiana, Ireland, Limerick, U.S, Kinsale, Europe, Novo

☆ These 5 portfolio stocks crushed the volatile market since our August Monthly Meeting
▼ + stars: | 2024-09-12 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

It's been a topsy-turvy stock market since the Club's August Monthly Meeting. These were two of our top performers since the August Monthly Meeting. The stock closed nearly 5% higher on the eve of the September Monthly Meeting. The S & P 500's health care sector is up 2.2% since the August Monthly Meeting, slightly outperforming the broad index's 1.8% rise in that timeframe. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: It's, We've, Eli Lilly, Estee Lauder, Jerome Powell, it's, DA Davidson, Goldman Sachs, Goldman, Andy Jassy's, TJX, Jensen Huang, Abbott, Jim Cramer's, Jim Cramer, Jim, Brendan Mcdermid Organizations: Dow Jones Industrial, Nasdaq, Investor, Federal, Procter, Gamble, Dover, Abbott Laboratories, TJX, Amazon, Micro Devices, Jackson, Bank of America, Telsey Advisory Group, JPMorgan, Oracle, Devices, AMD, Nvidia, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange Locations: seesaw, Wednesday's, U.S

☆ A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list
▼ + stars: | 2024-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule. Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

Persons: Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus Organizations: Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE Locations: Bristol, radiopharmaceuticals

☆ The next big market for weight-loss drugs: children
▼ + stars: | 2024-09-11 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Novo Nordisk's American rival, Eli Lilly, has also been testing obesity-beating drugs for children as young as six. Wegovy and similar drugs for weight loss have become a huge business. The drugs' success has made Novo Nordisk the most valuable company in Europe. AdvertisementChildhood obesityAn FDA approval on weight loss drugs for children could open up a new market for Novo Nordisk. In June, US Sen. Bernie Sanders announced that Novo Nordisk CEO Lars Jørgensen would testify before the committee on September 24 at a hearing focusing on the prices that Novo Nordisk charges Americans for their drugs, Ozempic and Wegovy.

Persons: —, Saxenda, Novo, Claudia Fox, Eli Lilly, Goldman Sachs, Wegovy, Sen, Bernie Sanders, Lars Jørgensen, Sanders Organizations: Service, BMI, Business, FDA, Financial Times, Novo Nordisk, Centers for Disease Locations: Madrid, Europe

☆ JPMorgan says this new player in the GLP-1 market could rally 45%
▼ + stars: | 2024-09-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

JPMorgan thinks Viking Therapeutics could be the next big name in the GLP-1 boom. Investors are awaiting more details about the oral version, expected in early November, as a possible catalyst for the stock. VKTX YTD mountain Viking Therapeutics stock. Some patients who take these popular obesity drugs suffer nausea and gastrointensinal effects that force them to stop treatment. Oral drugs also tend to be cheaper and easier to manufacture.

Persons: GLP, Eli Lilly, Viking, Hardik Parikh, Parikh, Wegovy, Eli Lilly's Zepbound Organizations: JPMorgan, Viking, Therapeutics, Novo Nordisk, Investors, Viking Therapeutics

The findings bring the phenomenon — and the controversy — of the latest new and powerful weight loss drugs to the youngest age group yet. The new trial looked at liraglutide, the active ingredient used in two of Novo Nordisk’s older GLP-1 drugs: Saxenda, a weight loss drug, and Victoza, a diabetes drug. So instead of looking at overall weight loss like in adult studies, they decided to focus more on BMI, which takes into account both weight and height. A spokesperson for Novo Nordisk said that it has submitted an application to the Food and Drug Administration to expand the approval of liraglutide for weight loss in children ages 6 to 11. Is 6 too young for a weight loss drug?

Persons: Roy Kim, “, ” Kim, Claudia Fox, Fox, Eli Lilly, ”, liraglutide, ” Fox, Sarah Armstrong, ” Armstrong, comorbidities, it’s, ” Wegovy, Zepbound, Shauna Levy, ” Levy Organizations: New England, of Medicine, Novo Nordisk, Cleveland Clinic, Centers for Disease Control, University of Minnesota, BMI, Food and Drug Administration, American Academy of Pediatrics, Duke University, Tulane Bariatric Center Locations: liraglutide, Ozempic, Ohio, U.S, New Orleans

☆ Sit out the September roller coaster with these steady stocks
▼ + stars: | 2024-09-09 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

A handful of stocks could prove to be smooth sailing for investors looking to ride out a historically volatile September. Stocks got off to a shaky start this month, with last week marking the worst performance since March 2023 for the S & P 500. Shares have advanced about 55% in 2024, and analysts polled by LSEG forecast nearly 11% upside ahead for the pharmaceutical stock. TJX YTD mountain TJX Companies stock. Analysts polled by LSEG forecast more than 12% upside ahead for TJX stock.

Persons: Stocks, Eli Lilly, TJX Organizations: CNBC Pro, CNBC, LSEG, Wall, Marshalls, Brands, Companies, Omnicom, Kroger Locations: Maxx

☆ Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Starbucks, Chipotle, Eli Lilly, Target, TJX Companies, Coinbase and more
▼ + stars: | 2024-08-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Stifel upgrades Starbucks to buy from hold Stifel upgraded the coffee chain following the management shakeup that included a new CEO. Jefferies upgrades Sportradar to buy from hold Jefferies upgraded the Swiss global sports tech company, saying it's becoming "increasingly attractive." Morgan Stanley reiterates Target as overweight Morgan Stanley said it's sticking with its overweight rating heading into Target 's earnings next week. Berenberg reiterates Eli Lilly as buy Berenberg raised its price target on the drugmaker to $1,050 per share from $1,000. TD Cowen upgrades Ilumina to buy from hold TD Cowen sees revenue growth ahead for the biotech company.

Persons: Wolfe, PulteGroup, rais, Brian Niccol, Baird, Tesla, it's bullish, Goldman Sachs, Goldman, Elliott, Wells, Equitrans, ETRN, Jefferies, it's, SRAD, Bernstein, Chipotle, Morgan Stanley, Berenberg, Eli Lilly, Lilly, circumspection, Ross, BURL, ROST, Oppenheimer, TD Cowen, mgmt Organizations: Stifel, RBC, Johnson, underperform RBC, Elliott Management, Barclays, Nvidia, JPMorgan downgrades Emerson, JPMorgan, Deutsche Bank, Deutsche, Ball Corp, Ball Corporation, Montrose Environmental, Stock, Intuit, Citi, Palo Alto, Bank of America, TJX Companies, Argus Locations: Florida, Underperform, Swiss, Montrose, QuickBooks, Burlington, Coinbase, China, Hershey

Several analysts raised their ratings and price targets on Starbucks a day after news that Chipotle CEO would take over at the coffee chain. Starbucks shares rallied on the news, while Chipotle shares fell. He also lowered his price target on shares to $685 from $750, which implies just 6% upside from Monday's close. Chipotle shares pulled back of 7% comes as decelerating trends and a sector rotation already impacted Chipotle's multiple. Since Niccol took the position of CEO in 2018, Chipotle shares surged more than 770%.

Persons: Bernstein, Fatima Boolani, Boolani, — Hakyung Kim, Eli Lilly Eli Lilly's, Berenberg, Lilly, Kerry Holford, " Holford, Morgan Stanley, Keith Weiss, Weiss, Hakyung Kim, Brian Niccol's, Danilo Gargiulo, Gargiulo, Niccol, Chipotle, Laxman Narasimhan, Brian Niccol, Baird, David Tarantino, Fred Imbert Organizations: CNBC, Citi, Palo Alto, Palo Alto Networks, pharma, Intuit, Starbucks, Deutsche Bank, SBUX Locations: Tuesday's

☆ Here are Tuesday's biggest analyst calls: Netflix, Amazon, Lyft, CrowdStrike, Dell, Disney, Hormel, Eli Lilly, Home Depot & more
▼ + stars: | 2024-08-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are the biggest calls on Wall Street on Tuesday: Wells Fargo initiates Rollins as overweight Wells says it's bullish on shares of the pest control company. Goldman Sachs reiterates Disney as buy Goldman said it's sticking with its buy rating following Disney's biennial D23 fan event in California. " Wells Fargo initiates ITeos Therapeutics at overweight Wells said in its initiation of coverage into ITeos that the biotech company has multiple catalysts ahead. Bank of America reiterates Lyft as buy The bank said the ride sharing company is trading at a "significant discount." Wells Fargo reiterates Home Depot as overweight Wells says investors should buy the dip in Home Depot shares following earnings Tuesday morning.

Persons: Wells, Rollins, it's bullish, Goldman Sachs, Goldman, Bernstein, WBD, BTIG, Eli Lilly, Stifel, Lyft Organizations: Wells Fargo, Disney, UBS, JPMorgan, Netflix, Mizuho, Palo Alto, Barclays, Dell, DELL, Citi, Sales, Warner Brothers Discovery, ITeos, " Bank of America, Bank of America, Co, McCormick &, Depot, Amazon Locations: California, Turkey

☆ 3-Stock Lunch: Starbucks, Eli Lilly and JetBlue
▼ + stars: | 2024-08-12 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: Starbucks, Eli Lilly and JetBlueScott Nations, Nations Indexes president, joins 'Power Lunch' to discuss stock plays for three stocks.

Persons: Eli Lilly Organizations: JetBlue Scott Nations

☆ Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross
▼ + stars: | 2024-08-12 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBiotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle RossMichelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.

Persons: Stempoint's Michelle Ross Michelle Ross, Eli Lilly Organizations: Biotech Locations: Stempoint

While keeping his outperform rating, Vijay Rakesh chopped $10 off his price target to $145. The Oreo maker should see above-average earnings growth, Jordan said, and the stock itself is a high-quality core holding. — Alex Harring 5:50 a.m.: UBS lays out earnings expectations for Nvidia UBS is remaining bullish on Nvidia heading into the artificial intelligence giant's earnings report. Analyst Timothy Arcuri reiterated his buy rating and $150 price target heading into earnings expected later this month. His price target of $23, up from $20, implies a gain of 28.3% over the next 12 months.

Persons: Piper Sandler, Vijay Rakesh, Rakesh, Alex Harring, Shaun Kelley, Kelley, — Alex Harring, Eli Lilly, Eli Lilly's, James Shin, Shin, Jefferies, Samad Samana, Samana, Goldman, Goldman Sachs, Mills, Leah Jordan, Jordan, Kraft Heinz, Timothy Arcuri, Arcuri, Patrick Moley, Morley, HOOD, Fred Imbert Organizations: CNBC, UBS, Mizuho, Micron, Seagate Technology, Western, Bank of America, Gaming, Consumer, Terre Haute, Kentucky Derby, Deutsche Bank, Par Technology, Jefferies, Conagra Brands, Hershey, Nvidia UBS, Nvidia Locations: Churchill, Northern, Northern Virginia, Kentucky, Robinhood

Search resuls for: "Eli Lilly"

25 mentions found